Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics

Journal of Nuclear Medicine

Volumn 41, Issue 10, 2000, Pages 1714-1724

  Bading, J R ^a   Alauddin, M M ^a   Fissekis, J D ^a   Shahinian, A H ^a   Joung, J ^a   Spector, T ^a   Conti, P S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

5 18F Fluorouracil; Chemotherapy; Colorectal cancer; PET; Pharmacokinetics

Indexed keywords

5 ETHYNYLURACIL; FLUORINE 18; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG METABOLISM; FEMALE; IMAGE ANALYSIS; IMAGE ENHANCEMENT; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT;

ANIMAL; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; FLUORINE RADIOISOTOPES; FLUOROURACIL; RADIOPHARMACEUTICALS; RATS; RATS, INBRED F344; SUPPORT, NON-U.S. GOV'T; TOMOGRAPHY, EMISSION-COMPUTED; URACIL;

EID: 0033770118     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil
2. Use and limitations of positron emission tomography in clinical pharmacokinetics/dynamics: Part II
3. The role of positron emission tomography in pharmacokinetic analysis
4. Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators
5. Fluorouracil in colorectal cancer: A tale of two drugs - Implications for biochemical modulation
6. Resistance to chemotherapeutic antimetabolites: A function of salvage pathway involvement and cellular response to DNA damage
7. Clinical pharmacology of 5-fluorouracil
8. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
9. Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors
10. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil
11. 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil
12. 5-Ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil
13. 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies
14. 18F-5-Fluorouracil studies in humans and animals
15. Dosimetry and preliminary human studies of [F-18]-5-fluorouracil
16. 19F nuclear magnetic resonance spectroscopy
17. Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation
18. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil
19. 18F-5-fluorouridine in rats
20. Development of F-18 5-fluorouracil and fluorodeoxyuridine as tracers of chemotherapeutic agents for liver cancer
21. Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin: Role of dose schedule and route of administration of leucovorin
22. 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats beating advanced colorectal carcinoma
23. Role of fluoropyrimidine schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma
24. The clinical use of sodium fluoride F-18 in bone photoscanning
25. Assay and time course of 5-fluorouracil into RNA of L 1210/0 ascites cells in vivo
26. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival
27. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
28. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma
29. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil
30. The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia
31. Analysis of nucleotide pools in animal cells
32. Long retention of high concentrations of 5-fluorouracil in human and murine tumors compared to plasma
33. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma
34. Transport of molecules across tumor vasculature
35. 18F-5-fluorodeoxyuridine in animals
36. 11C]thymidine PET imaging studies: Validation studies
37. A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC)
38. 2 x 2 daily) as first-line chemotherapy in patients with advanced breast cancer: A phase II study
39. Phase II study of eniluracil (776C85) and oral 5-fluorouracil (5FU) in patients with advanced squamous cell head and neck cancer (HNC)
40. DPD and TS gene expressions identify a high percentage of colorectal tumors responding to 5-FU